Table 15g. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Lactic Acidosis

Body
Table 15g. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Lactic Acidosis
Adverse Effects Associated ARVs Onset/Clinical Manifestations Estimated Frequency Risk Factors Prevention/Monitoring Management

Lactic Acidosis

NRTIs

  • ZDV
  • Less likely with 3TC, FTC, ABC, TAF, and TDF

Other Drugs

  • See the Risk Factors and Prevention/
    Monitoring columns for information regarding the toxicity of propylene glycol when LPV/r oral solution is used in neonates.

Onset

  • Generally after years of exposure

Presentation

  • Lactic acidosis may be clinically asymptomatic.

Lactic Acidosis May Also Present with Insidious Onset of a Combination of Signs and Symptoms

  • Generalized fatigue, weakness, and myalgias
  • Vague abdominal pain, weight loss, unexplained nausea, or vomiting
  • Dyspnea
  • Peripheral neuropathy

Note: Patients may present with acute multiorgan failure (e.g., fulminant hepatic failure, pancreatic failure, respiratory failure).

3TC, FTC, ABC, TAF, and TDF are less likely to induce clinically significant mitochondrial dysfunction than ZDV.

Adults

  • Female sex
  • High BMI
  • Chronic HCV infection
  • African American race
  • Coadministration of TDF with metformin
  • Overdose of propylene glycol
  • CD4 count <350 cells/mm3
  • Acquired riboflavin or thiamine deficiency
  • Possible pregnancy

Preterm Infants or Any Neonates Who Have Not Attained a Postmenstrual Age of 42 Weeks and a Postnatal Age of ≥14 Days

  • Exposure to propylene glycol, which is used as a diluent in LPV/r oral solution, because these newborns have a diminished ability to metabolize propylene glycol may lead to accumulation, increasing the risk of adverse events.

Prevention

  • Due to the presence of propylene glycol as a diluent, LPV/r oral solution should not be used in preterm neonates or any neonate who has not attained a postmenstrual age of 42 weeks and a postnatal age of ≥14 days.
  • Monitor for clinical manifestations of lactic acidosis and promptly adjust therapy.

Monitoring

Asymptomatic Patients

  • Routine measurement of serum lactate is not recommended.

Patients with Clinical Signs or Symptoms Consistent with Lactic Acidosis

  • Obtain blood lactate level.a
  • Additional diagnostic evaluations should include serum bicarbonate, anion gap, and/or arterial blood gas; amylase and lipase; serum albumin; and hepatic transaminases.

For Patients with Lactate 2.1–5.0 mmol/L (Confirmed with a Second Test)

  • Consider discontinuing all ARV drugs temporarily while conducting additional diagnostic work-up.

For Patients with Lactate >5.0 mmol/L (Confirmed with a Second Test)b or >10.0 mmol/L (Any One Test)

  • Discontinue all ARV drugs.
  • Provide supportive therapy (e.g., IV fluids; some patients may require sedation and respiratory support to reduce oxygen demand and ensure adequate oxygenation of tissues).

Anecdotal (Unproven) Supportive Therapies

  • Administer bicarbonate infusions, THAM, high doses of thiamine and riboflavin, and oral antioxidants (e.g., L-carnitine, co-enzyme Q10, vitamin C).

Following the resolution of clinical and laboratory abnormalities, resume therapy either with an NRTI-sparing regimen or a revised NRTI-containing regimen. Institute a revised NRTI-containing regimen with caution, using NRTIs that are less likely to induce mitochondrial dysfunction (ABC, TAF, TDF, FTC, or 3TC). Lactate should be monitored monthly for ≥3 months.

a Blood for lactate determination should be collected, without prolonged tourniquet application or fist clenching, into a pre-chilled, gray-top, fluoride-oxalate-containing tube and transported on ice to the laboratory to be processed within 4 hours of collection.

b Management can be initiated before receiving the results of the confirmatory test.

Key: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; BMI = body mass index; CD4 = CD4 T lymphocyte; FTC = emtricitabine; HCV = hepatitis C virus; IV = intravenous; LPV/r = lopinavir/ritonavir; NRTI = nucleoside reverse transcriptase inhibitor; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; THAM = tris (hydroxymethyl) aminomethane; ZDV = zidovudine

 

References